IL3 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, targeting chronic granulocytic leukemia (CML) cells using LAMP2b fused to an IL-3 fragment allows exosomes to inhibit CML cell growth in vitro and in vivo by loading Imatinib or siRNA targeting bcr-abl into engineered exosomes (Bellavia et al., 2017).